Loading...
Loading...
Immunomedics, Inc.
,a
biopharmaceutical company primarily focused on the development of monoclonal
antibody-based products for the targeted treatment of cancer, autoimmune and
other serious diseases, today announced that adult patients with relapsed or
refractory acute lymphocytic leukemia (ALL) reported a complete response (CR
and CRi) rate of 50% after receiving one cycle of treatment with epratuzumab
in combination with the chemotherapy agents, clofarabine and cytarabine.
Results from this Phase II S0910 study conducted by the Southwest Oncology
Group (SWOG) of the National Cancer Institute (NCI) were presented at the 2012
Annual Meeting of the American Society of Hematology by Anjali S. Advani, MD,
Principal Investigator and staff physician in the Department of the
Hematologic Oncology and Blood Disorders at Cleveland Clinic's Taussig Cancer
Institute, Cleveland, OH.
In addition to Cleveland Clinic, other clinical research centers participating
in this multicenter trial include City of Hope National Medical Center,
Duarte, CA; Stanford University School of Medicine, Stanford, CA; University
of Mississippi, Jackson, MS; University of Rochester Medical Center,
Rochester, NY; Baylor College of Medicine, Houston, TX; Fred Hutchinson Cancer
Research Center, and SWOG Statistical Center, Seattle, WA.
SWOG had previously reported a CR rate of 17% in adult patients with ALL using
only the combination of clofarabine and cytarabine. Because virtually all
immature B cells express CD22, which is the target of the Company's
proprietary humanized antibody, epratuzumab, the NCI-study group wanted to
evaluate the CR rate of combining the anti-CD22 antibody with the two
chemotherapeutic agents.
Twenty patients were initially accrued into the study to test whether the CR
rate is sufficiently high to warrant further investigation. After at least 2
complete responders were observed in the first 20 patients, an additional 12
patients were accrued.
Among the 32 eligible patients evaluated, the overall CR rate was 50% (95% CI
32-68%), including 10 CRs and 6 CRis. The null response rate in this protocol
was 10%, and the P-value comparing 50% to 10% is 1.2 x 10^-8 (P=0.000000012).
The median overall survival for the 32 eligible patients with follow-up
information was 4 months. Only 5 patients who achieved CR/CRi had their bone
marrow tested for minimal residual disease (MRD). Of these, only 1 patient
achieved a significant MRD response and this patient survived 11 months.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in